Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclosporine intracanalicular insert
- Development stage
- Phase 2
- Lead developer
- Ocular Therapeutix
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
OTX-CSI is a long-acting, preservative-free cyclosporine intracanalicular insert designed for the treatment of dry eye disease. It delivers a consistent dose of cyclosporine without preservatives over approximately 12 weeks. The insert resides in the canaliculus and occludes the punctum, releasing cyclosporine directly into the tear fluid.
02
Targets
Cyp (Cyclophilin family)CN (Calcineurin)
Beyond the preview
Go deeper on cyclosporine intracanalicular insert.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclosporine intracanalicular insert.